Holocene Advisors LP Has $116.69 Million Stake in Masimo Co. (NASDAQ:MASI)

Holocene Advisors LP lowered its position in shares of Masimo Co. (NASDAQ:MASI) by 15.6% during the third quarter, HoldingsChannel reports. The fund owned 875,159 shares of the medical equipment provider’s stock after selling 162,291 shares during the quarter. Holocene Advisors LP’s holdings in Masimo were worth $116,685,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also bought and sold shares of the company. NBC Securities Inc. raised its stake in shares of Masimo by 47.1% during the third quarter. NBC Securities Inc. now owns 228 shares of the medical equipment provider’s stock valued at $30,000 after acquiring an additional 73 shares during the last quarter. GAMMA Investing LLC increased its holdings in Masimo by 75.0% in the second quarter. GAMMA Investing LLC now owns 259 shares of the medical equipment provider’s stock valued at $33,000 after purchasing an additional 111 shares during the period. Northwestern Mutual Wealth Management Co. raised its position in Masimo by 133.3% during the 2nd quarter. Northwestern Mutual Wealth Management Co. now owns 350 shares of the medical equipment provider’s stock worth $44,000 after purchasing an additional 200 shares during the last quarter. HHM Wealth Advisors LLC lifted its holdings in Masimo by 25.0% during the 2nd quarter. HHM Wealth Advisors LLC now owns 625 shares of the medical equipment provider’s stock worth $79,000 after buying an additional 125 shares during the period. Finally, Lazard Asset Management LLC grew its position in shares of Masimo by 5,730.0% in the 1st quarter. Lazard Asset Management LLC now owns 583 shares of the medical equipment provider’s stock valued at $85,000 after buying an additional 573 shares during the last quarter. Institutional investors and hedge funds own 85.96% of the company’s stock.

Masimo Stock Performance

NASDAQ:MASI opened at $172.54 on Monday. The firm has a market capitalization of $9.24 billion, a P/E ratio of 118.99 and a beta of 0.97. Masimo Co. has a twelve month low of $91.60 and a twelve month high of $178.27. The company has a fifty day moving average of $149.24 and a 200-day moving average of $129.91. The company has a quick ratio of 1.11, a current ratio of 2.01 and a debt-to-equity ratio of 0.50.

Masimo (NASDAQ:MASI) last posted its quarterly earnings results on Tuesday, November 5th. The medical equipment provider reported $0.98 earnings per share for the quarter, beating the consensus estimate of $0.84 by $0.14. The firm had revenue of $504.60 million during the quarter, compared to the consensus estimate of $502.87 million. Masimo had a net margin of 3.85% and a return on equity of 14.98%. The business’s revenue was up 5.4% compared to the same quarter last year. During the same period in the previous year, the firm posted $0.63 earnings per share. As a group, sell-side analysts anticipate that Masimo Co. will post 4.03 EPS for the current year.

Analyst Ratings Changes

A number of research firms recently commented on MASI. Needham & Company LLC reaffirmed a “hold” rating on shares of Masimo in a research note on Wednesday, November 6th. Raymond James upgraded shares of Masimo from a “market perform” rating to an “outperform” rating and set a $170.00 price target for the company in a report on Wednesday, November 6th. Wells Fargo & Company upped their price objective on shares of Masimo from $160.00 to $171.00 and gave the company an “overweight” rating in a research note on Wednesday, November 6th. BTIG Research lifted their target price on shares of Masimo from $166.00 to $170.00 and gave the stock a “buy” rating in a research note on Monday, October 14th. Finally, Piper Sandler upped their price target on shares of Masimo from $165.00 to $180.00 and gave the company an “overweight” rating in a research report on Wednesday, November 6th. Three analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $167.00.

About Masimo

Masimo Corporation develops, manufactures, and markets various patient monitoring technologies, and automation and connectivity solutions worldwide. The company offers masimo signal extraction technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry; Masimo rainbow SET platform, including rainbow SET Pulse CO-Oximetry products that allows noninvasive monitoring of carboxyhemoglobin, methemoglobin, hemoglobin concentration, fractional arterial oxygen saturation, oxygen content, pleth variability index, rainbow pleth variability index, respiration rate from the pleth, and oxygen reserve index, as well as acoustic respiration monitoring, SedLine brain function monitoring, NomoLine capnography and gas monitoring, and regional oximetry.